CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Inclusion Criteria

• •1. ≥18 years old;
• •2. Sign on the informed consent;
• •3. Subjects must have histologically confirmed Large B-cell Lymphoma;
• •4. Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);
• •5. Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification;
• •6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;
• •7. Adequate organ function;
• •8. Adequate vascular access for leukapheresis procedure;
• •9. Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19;
• •10. Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel;
• •11. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.